National Health Act 1953 - Declaration under subsection 85(2AA) (16/11/1988)

Overview

The National Health Act 1953, enacted by the Australian Parliament, was introduced to establish and maintain high standards of health within the nation. One of its key objectives is to regulate the provision of pharmaceutical benefits, ensuring access to essential medications while managing costs effectively. The Pharmaceutical Benefits Declaration under sub-section 85(2AA) of the Act specifies certain drugs and medicinal preparations that are excluded from the coverage provided under Part VII, which deals with the listing of pharmaceutical benefits on the Pharmaceutical Benefits Scheme (PBS). This exclusion is intended to streamline the PBS by removing medications that are either considered obsolete, have limited therapeutic use, or are available through alternative means, thereby focusing resources on treatments that provide the greatest benefit to the population. The Declaration, which came into operation on 1 December 1953, is a legislative instrument that updates the Schedule of excluded items, reflecting changes in medical practice and therapeutic needs.

Scope and Application

The National Health Act 1953, specifically as amended by the Pharmaceutical Benefits Declaration under sub-section 85(2AA), applies to the pharmaceutical industry, healthcare providers, and consumers within Australia. This legislation primarily governs the provision of pharmaceutical benefits under the Pharmaceutical Benefits Scheme (PBS). It establishes the criteria for the inclusion and exclusion of drugs and medicinal preparations from the PBS, impacting their availability and the extent of government subsidies for these items. The Act applies nationally across the Commonwealth of Australia, thereby affecting all states and territories uniformly. The Declaration, effective from 1 December 1988, identifies specific drugs and medicinal preparations listed in the Schedule, which are no longer subject to the provisions of Part VII of the National Health Act 1953. This means that the named pharmaceuticals are excluded from the PBS, thereby affecting their subsidised availability to consumers. The scope of the Act is further extended and refined through subordinate instruments, which may provide additional details on the criteria for inclusion or exclusion from the PBS.

Key Provisions

The key operative sections of this Declaration under the National Health Act 1953 are defined in sections 85(2AA) and the accompanying Schedule (sections 2 and 3). Section 85(2AA) provides the authority for the Acting First Assistant Secretary, Health Benefits Division, to declare changes to the list of drugs and medicinal preparations covered under Part VII of the Act. Section 2 specifies the commencement date of this Declaration, which is 1 December 1988. Section 3 lists the specific drugs and medicinal preparations that will cease to be covered by the Act. This Act imposes the obligation on the specified drugs and medicinal preparations listed in the Schedule to no longer be considered for funding or coverage under Part VII of the National Health Act 1953. This means that as of the commencement date, these pharmaceuticals will not be subject to the provisions of the Pharmaceutical Benefits Scheme (PBS), which provides subsidies for certain medicines to make them more affordable and accessible to the public. In terms of consequences for breach, it is important to note that this Declaration does not explicitly state any offences, penalties, or consequences for non-compliance. However, any failure to adhere to the provisions of the National Health Act 1953 or its amendments could potentially result in legal action, fines, or other penalties as prescribed by the relevant laws and regulations. The maximum penalties for such breaches would be determined by the specific provisions of the National Health Act 1953 and any other applicable legislation.